dc.contributor.author | Bowyer, S | |
dc.contributor.author | Prithviraj, P | |
dc.contributor.author | Lorigan, P | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | McArthur, G | |
dc.contributor.author | Atkinson, V | |
dc.contributor.author | Millward, M | |
dc.contributor.author | Khou, M | |
dc.contributor.author | Diem, S | |
dc.contributor.author | Ramanujam, S | |
dc.contributor.author | Kong, B | |
dc.contributor.author | Liniker, E | |
dc.contributor.author | Guminski, A | |
dc.contributor.author | Parente, P | |
dc.contributor.author | Andrews, MC | |
dc.contributor.author | Parakh, S | |
dc.contributor.author | Cebon, J | |
dc.contributor.author | Long, GV | |
dc.contributor.author | Carlino, MS | |
dc.contributor.author | Klein, O | |
dc.date.accessioned | 2017-03-24T15:36:20Z | |
dc.date.issued | 2016-05 | |
dc.identifier.citation | British journal of cancer, 2016, 114 (10), pp. 1084 - 1089 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/528 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/bjc.2016.107 | |
dc.description.abstract | Background Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.Methods We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg(-1) for a maximum of four doses.Results Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3-5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3-5 pneumonitis leading to death in one patient.Conclusions Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance. | |
dc.format | Print-Electronic | |
dc.format.extent | 1084 - 1089 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Melanoma | |
dc.subject | Skin Neoplasms | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Antineoplastic Agents | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Treatment Outcome | |
dc.subject | Drug Administration Schedule | |
dc.subject | Retrospective Studies | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Ipilimumab | |
dc.title | Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-03-14 | |
rioxxterms.versionofrecord | 10.1038/bjc.2016.107 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-sa/4.0 | |
rioxxterms.licenseref.startdate | 2016-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 10 | |
pubs.notes | 12 months | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 114 | |
pubs.embargo.terms | 12 months | |
icr.researchteam | Melanoma and Kidney Cancer | en_US |
dc.contributor.icrauthor | Larkin, James | |